Twitter updates
Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.
Weekly Dose: A Roundup of Top Stories for Primary Care Physicians
PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.
FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults
Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces
Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.
Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD
The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.
